Increase of Japan's medical expenditure slowed to 1.7% in 2012

17 September 2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) reported approximate medical expenditure (AME) for the fiscal year 2012 that ended in March. Although costs for work-place injuries and some out-of-pocket items are yet to be included, the AME - accounting for 98% of the National Health Expenditure (NHE) - is a quick and accurate indicator of trends in the NHE, which takes a year and a half to be finalized, reports The Pharma Letter’s local analyst.

The AME increased by 640 billion yen ($6.44 billion) or 1.7% to 38.4 trillion yen in 2012. Payments for elderly patients (aged above 70) accounted for 75% or 480 billion yen of the total increase. For the age bracket, daily medical cost per patient increased 2.6% to 14,800 yen in 2012 and annual medical cost per capita became 804,000 yen compared to overall average of 301,000 yen. For the population aged above 70, the per capita cost became 4.4 times larger and the group accounted for 17% of the total population and 45% of the total medical spending.

New drugs also increasing medical costs

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics